Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$53.92 -0.2%	$46.52	$21.02 ▼ $58.40	$4.31B	-0.16	1.03 million shs	4.37 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
SWTX SpringWorks Therapeutics	$46.96 0.0%	$45.50	$28.21 ▼ $62.00	$3.54B	0.7	2.48 million shs	2.32 million shs
ZYME Zymeworks	$12.82 +2.8%	$12.12	$8.21 ▼ $17.70	$891.98M	1.17	583,715 shs	453,042 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	-0.20%	-2.67%	+16.31%	+24.56%	+126.08%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	+4.29%
SWTX SpringWorks Therapeutics	-0.02%	+0.21%	+1.03%	+1.03%	+30.23%
ZYME Zymeworks	+2.81%	+4.74%	+11.09%	+3.81%	+52.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.6239 of 5 stars	3.5	1.0	0.0	4.7	1.8	1.7	0.0
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	1.509 of 5 stars	3.1	2.0	0.0	0.0	2.3	0.0	0.6
ZYME Zymeworks	1.8834 of 5 stars	3.5	0.0	0.0	0.0	2.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$82.50	53.00% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	11.95% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.00	63.81% Upside

Current Analyst Ratings Breakdown

Latest ZYME, AKRO, MOR, and SWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/20/2025	ZYME Zymeworks	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/20/2025	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	AKRO Akero Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
5/12/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$47.00 ➝ $47.00
4/30/2025	SWTX SpringWorks Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$74.00 ➝ $47.00
4/29/2025	SWTX SpringWorks Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
4/29/2025	SWTX SpringWorks Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$66.00 ➝ $47.00
4/28/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$77.00 ➝ $47.00
4/28/2025	SWTX SpringWorks Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/28/2025	SWTX SpringWorks Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$63.00 ➝ $47.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
SWTX SpringWorks Therapeutics	$191.59M	18.47	N/A	N/A	$6.47 per share	7.26
ZYME Zymeworks	$93.38M	9.55	N/A	N/A	$6.63 per share	1.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
SWTX SpringWorks Therapeutics	-$258.13M	-$3.41	N/A	N/A	N/A	-115.60%	-51.10%	-43.80%	8/6/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$1.49	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	7/30/2025 (Estimated)

Latest ZYME, AKRO, MOR, and SWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/8/2025	N/A	ZYME Zymeworks	-$0.45	-$0.30	+$0.15	N/A	$20.65 million	$27.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.03	16.80	16.80
MOR MorphoSys	4.98	1.38	1.38
SWTX SpringWorks Therapeutics	N/A	4.33	4.18
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
MOR MorphoSys	18.38%
SWTX SpringWorks Therapeutics	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
MOR MorphoSys	0.05%
SWTX SpringWorks Therapeutics	7.83%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	69.45 million	Optionable
ZYME Zymeworks	460	69.58 million	67.56 million	Optionable

ZYME, AKRO, MOR, and SWTX Headlines

Recent News About These Companies

Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

June 25 at 3:35 AM | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus Price Target from Brokerages

June 24 at 1:16 AM | americanbankingnews.com

Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

June 20, 2025 | zacks.com

Rhumbline Advisers Has $985,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)

June 20, 2025 | marketbeat.com

Duncan Williams Asset Management LLC Buys Shares of 22,095 Zymeworks Inc. (NYSE:ZYME)

June 19, 2025 | marketbeat.com

Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500

June 18, 2025 | kalkinemedia.com

SG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME)

June 17, 2025 | marketbeat.com

Assenagon Asset Management S.A. Sells 147,184 Shares of Zymeworks Inc. (NYSE:ZYME)

June 15, 2025 | marketbeat.com

Zymeworks (NYSE:ZYME) Shares Gap Down - Time to Sell?

June 13, 2025 | marketbeat.com

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

June 12, 2025 | seekingalpha.com

Bank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME)

June 12, 2025 | marketbeat.com

Wellington Management Group LLP Decreases Position in Zymeworks Inc. (NYSE:ZYME)

June 5, 2025 | marketbeat.com

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?

June 4, 2025 | zacks.com

Zymeworks’ zanidatamab gains approval in China for biliary tract cancer

June 2, 2025 | msn.com

Zymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLC

June 2, 2025 | marketbeat.com

Voloridge Investment Management LLC Buys Shares of 43,708 Zymeworks Inc. (NYSE:ZYME)

May 31, 2025 | marketbeat.com

Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestone

May 30, 2025 | endpts.com

China's NMPA Approves Zymeworks' Ziihera for HER2-High Biliary Tract Cancer

May 30, 2025 | precisionmedicineonline.com

Zymeworks’ zanidatamab approved in China

May 30, 2025 | thepharmaletter.com

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge

May 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
By Chris Markoch | May 29, 2025
View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
3 Stocks Set to Double—And There's Still Time to Buy
By Nathan Reiff | June 12, 2025
View 3 Stocks Set to Double—And There's Still Time to Buy
More Than a Monetary Metal: Silver's Case for Outperformance
By Jeffrey Neal Johnson | June 22, 2025
View More Than a Monetary Metal: Silver's Case for Outperformance
Tesla: Why Analysts Think It Could Jump Another 47%
By Sam Quirke | May 27, 2025
View Tesla: Why Analysts Think It Could Jump Another 47%
Trump Orders Nuclear Overhaul: These 3 Stocks Stand to Benefit
By Dan Schmidt | May 28, 2025
View Trump Orders Nuclear Overhaul: These 3 Stocks Stand to Benefit

ZYME, AKRO, MOR, and SWTX Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$53.92 -0.11 (-0.20%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$53.96 +0.05 (+0.08%)

As of 08:00 AM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 06/23/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

SpringWorks Therapeutics NASDAQ:SWTX

$46.96 -0.01 (-0.02%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$46.96 0.00 (0.00%)

As of 08:15 AM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Zymeworks NYSE:ZYME

$12.82 +0.35 (+2.81%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$12.82 -0.01 (-0.04%)

As of 06/24/2025 07:47 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time